📊 MEDP Key Takeaways
Is MEDP a Good Investment? Thesis Analysis
Medpace demonstrates exceptional financial health with robust profitability (21.1% operating margin, 17.8% net margin), generating strong free cash flow of $681.9M (26.9% FCF margin) with zero long-term debt. Revenue growth of 20% YoY combined with outstanding returns on equity (98.3%) and assets (22.8%) indicates highly efficient capital deployment in a growing clinical research services market.
Why Buy MEDP? Key Strengths
- Exceptional profitability with 21.1% operating margin and 17.8% net margin
- Outstanding free cash flow generation of $681.9M with 26.9% FCF margin
- Zero long-term debt and strong balance sheet with $497M cash reserves
- Exceptional return metrics (ROE 98.3%, ROA 22.8%) indicating superior capital efficiency
- 20% revenue growth YoY demonstrating strong market demand
- EPS growth of 21% YoY exceeding revenue growth indicates operational leverage
MEDP Investment Risks to Consider
- Current ratio of 0.74x indicates potential short-term liquidity constraints that warrant monitoring
- Net income flat YoY (0% growth) despite 20% revenue growth suggests margin compression or one-time items
- High insider trading activity (8 Form 4 filings in 90 days) may indicate management uncertainty or opportunistic selling
- Clinical research services sector exposure to regulatory changes and client concentration risks
- Dependency on continued strong client demand and contract renewals for growth sustainability
Key Metrics to Watch
- Revenue growth sustainability and year-over-year comparisons
- Net income and EPS trends relative to revenue growth to monitor margin expansion
- Operating cash flow consistency and free cash flow generation
- Current ratio improvement and short-term liquidity position
- Operating margin maintenance or expansion in future periods
MEDP Financial Metrics
💡 AI Analyst Insight
The 26.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
MEDP Profitability Ratios
MEDP vs Healthcare Sector
How Medpace Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MEDP Overvalued or Undervalued?
Based on fundamental analysis, Medpace Holdings, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MEDP Balance Sheet & Liquidity
MEDP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Medpace Holdings, Inc.'s revenue has grown significantly by 121% over the 5-year period, indicating strong business expansion. The most recent EPS of $8.88 reflects profitable operations.
MEDP Growth Metrics (YoY)
MEDP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $533.3M | $88.4M | $3.01 |
| Q2 2025 | $528.1M | $88.4M | $2.75 |
| Q1 2025 | $511.0M | $102.6M | $3.20 |
| Q3 2024 | $492.5M | $61.1M | $2.22 |
| Q2 2024 | $460.9M | $61.1M | $1.93 |
| Q1 2024 | $434.1M | $72.9M | $2.27 |
| Q3 2023 | $383.7M | $49.4M | $2.05 |
| Q2 2023 | $351.2M | $49.4M | $1.46 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MEDP Capital Allocation
MEDP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Medpace Holdings, Inc. (CIK: 0001668397)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773953443.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773953138.xml | View → |
| Feb 18, 2026 | 4 | xslF345X05/wk-form4_1771451955.xml | View → |
| Feb 17, 2026 | 4 | xslF345X05/wk-form4_1771365558.xml | View → |
| Feb 17, 2026 | 4 | xslF345X05/wk-form4_1771364585.xml | View → |
❓ Frequently Asked Questions about MEDP
What is the AI rating for MEDP?
Medpace Holdings, Inc. (MEDP) has an AI rating of STRONG BUY with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MEDP's key strengths?
Claude: Exceptional profitability with 21.1% operating margin and 17.8% net margin. Outstanding free cash flow generation of $681.9M with 26.9% FCF margin.
What are the risks of investing in MEDP?
Claude: Current ratio of 0.74x indicates potential short-term liquidity constraints that warrant monitoring. Net income flat YoY (0% growth) despite 20% revenue growth suggests margin compression or one-time items.
What is MEDP's revenue and growth?
Medpace Holdings, Inc. reported revenue of $2.5B.
Does MEDP pay dividends?
Medpace Holdings, Inc. does not currently pay dividends.
Where can I find MEDP SEC filings?
Official SEC filings for Medpace Holdings, Inc. (CIK: 0001668397) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MEDP's EPS?
Medpace Holdings, Inc. has a diluted EPS of $15.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MEDP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Medpace Holdings, Inc. has a STRONG BUY rating with 87% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MEDP stock overvalued or undervalued?
Valuation metrics for MEDP: ROE of 98.3% (sector avg: 15%), net margin of 17.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy MEDP stock in 2026?
Our dual AI analysis gives Medpace Holdings, Inc. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is MEDP's free cash flow?
Medpace Holdings, Inc.'s operating cash flow is $713.2M, with capital expenditures of $31.4M. FCF margin is 26.9%.
How does MEDP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.8% (avg: 12%), ROE 98.3% (avg: 15%), current ratio 0.74 (avg: 2).